Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Multiple of Ten Bearish | Other | 1.54% | |
| Wide Bands | Range Expansion | 1.54% | |
| Multiple of Ten Bearish | Other | 0.98% | |
| Wide Bands | Range Expansion | 0.98% | |
| MACD Bearish Signal Line Cross | Bearish | -0.05% |
| Alert | Time |
|---|---|
| Possible NR7 | about 15 hours ago |
| Possible Inside Day | about 15 hours ago |
| 10 DMA Resistance | about 19 hours ago |
| Up 2% | about 19 hours ago |
| Up 1% | about 19 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/05/2024
Rhythm Pharmaceuticals, Inc. Description
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Peptides Peptide Hormones Metabolic Disorders Monogenic Genetic Disorder Leptin Melanocortin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 68.58 |
| 52 Week Low | 31.525 |
| Average Volume | 518,334 |
| 200-Day Moving Average | 45.82 |
| 50-Day Moving Average | 53.34 |
| 20-Day Moving Average | 57.54 |
| 10-Day Moving Average | 60.25 |
| Average True Range | 2.81 |
| RSI (14) | 57.63 |
| ADX | 22.94 |
| +DI | 27.07 |
| -DI | 20.14 |
| Chandelier Exit (Long, 3 ATRs) | 60.15 |
| Chandelier Exit (Short, 3 ATRs) | 56.04 |
| Upper Bollinger Bands | 69.26 |
| Lower Bollinger Band | 45.83 |
| Percent B (%b) | 0.6 |
| BandWidth | 40.71 |
| MACD Line | 2.23 |
| MACD Signal Line | 2.53 |
| MACD Histogram | -0.2916 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 61.82 | ||||
| Resistance 3 (R3) | 61.72 | 60.98 | 61.51 | ||
| Resistance 2 (R2) | 60.98 | 60.50 | 61.04 | 61.40 | |
| Resistance 1 (R1) | 60.46 | 60.21 | 60.72 | 60.57 | 61.30 |
| Pivot Point | 59.73 | 59.73 | 59.86 | 59.78 | 59.73 |
| Support 1 (S1) | 59.21 | 59.25 | 59.47 | 59.31 | 58.58 |
| Support 2 (S2) | 58.47 | 58.95 | 58.53 | 58.48 | |
| Support 3 (S3) | 57.95 | 58.47 | 58.37 | ||
| Support 4 (S4) | 58.06 |
